15 completed, 2 terminated. 13 Phase 1, 4 Phase 2.
By phase and status
Follow TRPC inhibitor BI 1358894: new trials by email Literature Review of TRPC inhibitor BI 1358894 trials Research Report on TRPC inhibitor BI 1358894
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
Yasmin®, BI 1358894 - Healthy | Phase 1 | Terminated | Boehringer Ingelheim | 29 | 2023-09-08 | 2025-02-24 |
A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food
BI 1358894, intended Commercial Formulation (iCF) (T), BI 1358894, Trial Formulation 2 (TFII) (R) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2022-01-14 | 2025-02-26 |
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
BI 1358894, Placebo - Post-Traumatic Stress Disorder | Phase 2 | Completed | Boehringer Ingelheim | 318 | 2021-12-07 | 2024-11-07 |
A Study in Healthy Men and Women to Test Whether BI 1358894 Influences the Amount of Bupropion in the Blood
Elontril, BI 1358894 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 18 | 2021-06-30 | 2025-02-24 |
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
BI 1358894, Placebo, Quetiapine - Depressive Disorder, Major | Phase 2 | Completed | Boehringer Ingelheim | 389 | 2020-11-20 | 2025-03-06 |
A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
BI 1358894, Placebo - Borderline Personality Disorder | Phase 2 | Completed | Boehringer Ingelheim | 390 | 2020-11-13 | 2024-01-30 |
A Study in Healthy Men to Test How BI 1358894 is Taken up and Handled by the Body
[14C]-radiolabelled BI 1358894, BI 1358894 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 15 | 2020-10-19 | 2025-02-27 |
A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood
BI 1358894, BI 1358894 (C-14) intravenous solution - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 12 | 2020-07-13 | 2025-03-30 |
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
BI 1358894, Placebo - Depressive Disorder, Major | Phase 2 | Terminated | Boehringer Ingelheim | 45 | 2020-06-22 | 2023-06-13 |
A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
Rosuvastatin, BI 1358894, Dabigatran etexilate - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 26 | 2019-10-07 | 2025-02-27 |
A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms
BI 1358894, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 20 | 2019-04-18 | 2025-03-19 |
A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood
BI 1358894 (B), BI 1358894 (C), BI 1358894 (D) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2019-04-08 | 2025-02-28 |
A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men
Placebo, Dose group 1 - 50 mg BI 1358894, Dose group 2 - 100 mg BI 1358894 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2019-03-25 | 2025-02-26 |
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1358894 in the Blood
BI 1358894, Itraconazole - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 16 | 2019-03-19 | 2025-02-21 |
A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
BI 1358894, Placebo matching BI 1358894, Citalopram - Depressive Disorder, Major | Phase 1 | Completed | Boehringer Ingelheim | 73 | 2019-03-12 | 2025-02-25 |
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 1358894 Affects the Way the Body Breaks Down Midazolam
BI 1358894, Placebo, Midazolam - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 50 | 2018-12-18 | 2025-04-03 |
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood
Placebo, BI 1358894, BI 1358894 (Test) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 83 | 2017-07-18 | 2025-03-25 |
Conditions studied
Depressive Disorder, Major (3) · Borderline Personality Disorder (1) · Stress Disorders, Post-Traumatic (1)
Sponsors
Boehringer Ingelheim (17)
Countries
Germany (12) · United States (4) · Japan (3) · Netherlands (3) · Poland (3) · Argentina (2) · Australia (2) · Bulgaria (2) · Czechia (2) · France (2) · Mexico (2) · Spain (2) · Sweden (2) · Belgium (1) · Canada (1)
Results publications
PMID 38019355, PMID 36343427, PMID 36375174, PMID 38019356, PMID 38656736, PMID 39715042, PMID 39832346, PMID 40900110
NIH funding
2018 (4), 2017 (2), 2019 (2)